Skip to content
Breast cancer, MAP Kinase, RAS-RAF pathway

Cancer Research Excellence Program (CREP)

Program Overview

Sysmex Inostics is calling for applications to its Cancer Research Excellence Program.

CREP is a competitive research support program that provides select applicants, performing solid tumor research, free access to our highly-sensitive Plasma-Safe-SeqS (PSS) NGS tests: 

  • BC-SEQ, 
  • MAPK-SEQ and 
  • RAS-RAF-SEQ.

Program Details

The application process for CREP begins with applicants submitting a short, 2 to 5 minute, Research Proposal Form. All applications must be received by April 30.

Once received, each proposal is reviewed for scientific soundness, feasibility, ethics, and overall alignment with SII’s priorities. Authors of approved RPFs will be contacted via email and/or phone within 30 days of the submission deadline and will be asked to provide a detailed research protocol. Once protocols have been reviewed and approved, awardees will be provided a contract and other information necessary begin working with Sysmex Inostics Inc.

Eligibility Requirements:

In order to be eligible, your organization must:

  • NOT currently be working with Sysmex Inostics on any projects
  • Be performing, or planning to perform solid tumor research, whereas BC-SEQ, MAPK-SEQ or RAS-RAF-SEQ analysis could be beneficial
  • Be located in the United States
  • All specimens for the study should be available to be tested by 12/21/22

We look forward to receiving your <application>!

Have questions? Contact us

Authors of qualified submissions will be entered to win one of TWO $250 Amazon Gift cards.

Application Process

  • Submit the completed short Research Proposal Form (RPF) which can be downloaded here. All applications should be received by March 31.
  • Once received, each proposal is reviewed for scientific soundness, feasibility, ethics and overall alignment with SII’s priorities. Authors of approved RPFs will be contacted via email and/or phone within 30 days and will be asked to provide a detailed research protocol. Once protocols have been reviewed and approved, awardees will be provided a contract and other information necessary to begin working with SII.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc et metus id ligula malesuada placerat sit amet quis enim. Aliquam erat volutpat. In pellentesque scelerisque auctor. Ut porta lacus eget nisi fermentum lobortis. Vestibulum facilisis tempor ipsum, ut rhoncus magna ultricies laoreet. Proin vehicula erat eget libero accumsan iaculis.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc et metus id ligula malesuada placerat sit amet quis enim. Aliquam erat volutpat. In pellentesque scelerisque auctor. Ut porta lacus eget nisi fermentum lobortis. Vestibulum facilisis tempor ipsum, ut rhoncus magna ultricies laoreet. Proin vehicula erat eget libero accumsan iaculis.

ASSAY GENE CONTENT SAMPLE TYPE SENSITIVITY INTENDED USE
BC-SEQ AKT1, ERBB2, ESR1, KRAS, PIK3CA, TP53 Plasma or Buffy Coat (whole blood cells) from Streck cfDNA BCT or EDTA tubes Detects down to 0.03% mutant allele frequency (MAF) Therapy selection, monitor treatment response, minimal residual disease (MRD) detection and recurrence surveillance. This assay can also be used for adjudication of suspected non-tumor CHIP/Germline mutations.
RAS-RAF-SEQ AKT1, BRAF, KRAS, NRAS, PIK3CA3 Plasma or Buffy Coat (whole blood cells) from Streck cfDNA BCT tubes Detects down to 0.03% mutant allele frequency (MAF) Therapy selection, monitor treatment response and disease dynamics. This assay can also be used for adjudication of suspected non-tumor CHIP/Germline mutations.
MAPK-SEQ AR, BRAF, HRAS, KRAS, MAP2K1, MAP2K2, MAPK1, MAPK3, MTOR, NRAS, RAC1, RAF1 Whole blood Therapy selection, monitor treatment response, minimal residual disease (MRD) detection and recurrence surveillance.

GET RESEARCH SUPPORT

STILL HAVE QUESTIONS

<

About Sysmex Inostics

Sysmex Inostics, Inc., a subsidiary of Japan’s Sysmex Corporation, is a Baltimore-based biotechnology firm and CLIA-certified lab offering biomarker testing to accelerate the development of personalized medicine. Our goal is to transform the future of health, so life’s potential is not determined by a diagnosis of cancer and other devasting diseases. Utilizing its patented technologies, Sysmex Inostics can detect rare and minute traces of some of the world’s most elusive diseases, allowing for actionable insights to treat patients most effectively and enable them to live their fullest life beyond diagnosis.


Since 2008, we have played a significant role in solid tumor and liquid cancer discoveries serving the pharmaceutical, clinical, and research communities with the first commercially available liquid biopsy technology, OncoBEAM™. Now with our next generation sequencing (NGS) Plasma-Safe-SeqS technology panels, we empower more accurate detection of low-frequency biomarkers with ultra-sensitive 0.03% to 0.05% allele frequency from a simple blood draw to expedite studies and uncover deeper insights into therapy response.

We offer CLIA validated NGS testing services for

  • AML
  • breast cancer
  • HPV16/18 quantification
  • HNSCC
  • solid tumors impacted by RAS-RAF and PI3K signaling pathways.
  • In 2021, Sysmex Corporation announced a global strategic alliance with QIAGEN® to provide custom cancer companion diagnostics (CDx) utilizing Plasma-Safe-SeqS technology. The alliance is intended to promote early clinical implementation of Sysmex Inostics’ technology to expedite clinical trial timelines for pharmaceutical companies that develop molecularly targeted drugs for cancer.